title: The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2.
abstract: Fever has been shown to be elicited by prostaglandin E(2) (PGE(2)) binding to its receptors on thermoregulatory neurons in the anterior hypothalamus. The signals that trigger PGE(2) production are thought to include proinflammatory cytokines, such as IL-6. However, although the presence of IL-6 is critical for fever, IL-6 by itself is not or only weakly pyrogenic. Here we examined the relationship between IL-6 and PGE(2) in lipopolysaccharide (LPS)-induced fever. Immune-challenged IL-6 knockout mice did not produce fever, in contrast to wild-type mice, but the expression of the inducible PGE(2)-synthesizing enzymes, cyclooxygenase-2 and microsomal prostaglandin E synthase-1, was similarly up-regulated in the hypothalamus of both genotypes, which also displayed similarly elevated PGE(2) levels in the cerebrospinal fluid. Nevertheless, both wild-type and knockout mice displayed a febrile response to graded concentrations of PGE(2) injected into the lateral ventricle. There was no major genotype difference in the expression of IL-1beta and TNFalpha or their receptors, and pretreatment of IL-6 knockout mice with soluble TNFalpha receptor ip or intracerebroventricularly or a cyclooxygenase-2 inhibitor ip did not abolish the LPS unresponsiveness. Hence, although IL-6 knockout mice have both an intact PGE(2) synthesis and an intact fever-generating pathway downstream of PGE(2), endogenously produced PGE(2) is not sufficient to produce fever in the absence of IL-6. The findings suggest that IL-6 controls some factor(s) in the inflammatory cascade, which render(s) IL-6 knockout mice refractory to the pyrogenic action of PGE(2), or that it is involved in the mechanisms that govern release of synthesized PGE(2) onto its target neurons.
authors.affiliation: Department of Clinical and Experimental Medicine, Division of Cell Biology, Linköping University, Faculty of Health Sciences, Linköping, Sweden. camni@ibk.liu.se
authors.forename: Camilla
authors.initials: C
authors.lastname: Nilsberth
authors.forename: Louise
authors.initials: L
authors.lastname: Elander
authors.forename: Namik
authors.initials: N
authors.lastname: Hamzic
authors.forename: Maria
authors.initials: M
authors.lastname: Norell
authors.forename: Johanna
authors.initials: J
authors.lastname: Lönn
authors.forename: Linda
authors.initials: L
authors.lastname: Engström
authors.forename: Anders
authors.initials: A
authors.lastname: Blomqvist
mesh_terms: D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism* / Q000494:pharmacology*; D005334:Fever / Q000139:chemically induced*; D005838:Genotype; D007118:Immunoassay; D007150:Immunohistochemistry; D015850:Interleukin-6 / Q000235:genetics / Q000494:pharmacology* / Q000502:physiology*; D007555:Isoxazoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014781:Viscera / Q000378:metabolism
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D015850:Interleukin-6; D007555:Isoxazoles; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; C409945:parecoxib; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D015232:Dinoprostone